相关实验视频

Updated: May 12, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

缺乏RYR2的人类模型识别了处理和代谢功能障碍影响药理反应

Linda Starnes¹, Andrew Hall², Damla Etal³

¹Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Frontiers in cardiovascular medicine

|July 23, 2024

概括

研究人员设计了一个具有缺乏瑞诺丁受体2 (RYR2) 的人类心肌细胞模型,以研究心力衰竭. 这种模型揭示了药物反应和代谢变化的改变,有助于发现治疗心脏病的药物.

科学领域:

心血管研究研究心血管研究
遗传学和基因组学遗传学和基因组学
药理学药理学是指药理学的学科.

背景情况:

处理对于心脏功能至关重要;RYR2缺乏与心力衰竭有关.
人类诱导的多能干细胞 (hiPSC) 和CRISPR/Cas9基因编辑为疾病建模提供了强大的工具.
了解疾病状态中的差异性药物反应对于准确的临床结果预测至关重要.

研究的目的:

使用hiPSCs和CRISPR/Cas9.9创建和描述一个缺乏RYR2的人类心肌细胞模型.
研究RYR2缺乏对药理反应的影响,特别是对L型通道抑制剂的影响.
揭示与心肌细胞RYR2缺乏相关的新分子和代谢见解.

主要方法:

在hiPSC中通过CRISPR/Cas9基因编辑生成RYR2缺乏的人类心肌细胞.
工程心肌细胞的表型特征.
蛋白质组分析以确定蛋白质表达和代谢途径的变化.

主要成果:

缺乏RYR2的心肌细胞模拟了心力衰竭的各个方面.
观察到对L型通道抑制剂的药理学反应不同.
已确定结构蛋白的表达变化 (CSRP3,SLMAP) 和代谢变化 (酸路径上调,氧化还原敏感性增加).

结论:

开发的RYR2缺乏心肌细胞模型是研究心脏功能障碍的宝贵工具.
该模型有助于在处理和代谢变化的背景下研究药理反应.
它可以更好地将药物疗效和安全性研究结果从体外模型转化为疾病状态,从而有可能加速药物发现.

关键词:

处理处理处理处理心血管在体外模型中的心血管模型心脏衰竭是因为心脏衰竭.这就是hiPSC-CMs.酸酸盐路径的酸.氨酸受体2 氨酸受体2

更多相关视频

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

相关概念视频

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...